{"id":"https://openalex.org/W2245355156","doi":"https://doi.org/10.1200/jco.2005.23.16_suppl.4118","title":"Phase I trial of fixed dose rate infusion (FDRI) gemcitabine (GEM) with gefitinib in patients with advanced pancreatic carcinoma","display_name":"Phase I trial of fixed dose rate infusion (FDRI) gemcitabine (GEM) with gefitinib in patients with advanced pancreatic carcinoma","publication_year":2005,"publication_date":"2005-06-01","ids":{"openalex":"https://openalex.org/W2245355156","doi":"https://doi.org/10.1200/jco.2005.23.16_suppl.4118","mag":"2245355156"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2005.23.16_suppl.4118","doi":"https://doi.org/10.1200/jco.2005.23.16_suppl.4118","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2005.23.16_suppl.4118","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5069923958","display_name":"Benedito A. Carneiro","orcid":"https://orcid.org/0000-0002-5468-1126","observed_orcids":["https://orcid.org/0000-0002-5468-1126"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"B. Carneiro","raw_affiliation_strings":["Evanston Northwestern Healthcare, Evanston, IL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Evanston Northwestern Healthcare, Evanston, IL","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5039387801","display_name":"Randall E. Brand","orcid":"https://orcid.org/0000-0002-4136-3313","observed_orcids":["https://orcid.org/0000-0002-4136-3313"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"R. Brand","raw_affiliation_strings":["Evanston Northwestern Healthcare, Evanston, IL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Evanston Northwestern Healthcare, Evanston, IL","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5076961581","display_name":"Elita Fine","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"E. Fine","raw_affiliation_strings":["Evanston Northwestern Healthcare, Evanston, IL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Evanston Northwestern Healthcare, Evanston, IL","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5061549319","display_name":"Richard H. Knop","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"R. Knop","raw_affiliation_strings":["Evanston Northwestern Healthcare, Evanston, IL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Evanston Northwestern Healthcare, Evanston, IL","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5068737034","display_name":"Janardan D. Khandekar","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"J. Khandekar","raw_affiliation_strings":["Evanston Northwestern Healthcare, Evanston, IL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Evanston Northwestern Healthcare, Evanston, IL","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5065303762","display_name":"William J. Uhlig","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"W. Uhlig","raw_affiliation_strings":["Evanston Northwestern Healthcare, Evanston, IL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Evanston Northwestern Healthcare, Evanston, IL","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5007560050","display_name":"Gershon Y. Locker","orcid":"https://orcid.org/0000-0002-6869-8738","observed_orcids":["https://orcid.org/0000-0002-6869-8738"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"G. Y. Locker","raw_affiliation_strings":["Evanston Northwestern Healthcare, Evanston, IL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Evanston Northwestern Healthcare, Evanston, IL","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":4,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"23","issue":"16_suppl","first_page":"4118","last_page":"4118"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10231","display_name":"Pancreatic and Hepatic Oncology Research","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10231","display_name":"Pancreatic and Hepatic Oncology Research","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10760","display_name":"Pancreatitis Pathology and Treatment","score":0.00039999998989515007,"subfield":{"id":"https://openalex.org/subfields/2746","display_name":"Surgery"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11752","display_name":"Cancer Treatment and Pharmacology","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/gemcitabine","display_name":"gemcitabine","score":0.8629999756813049},{"id":"https://openalex.org/keywords/gefitinib","display_name":"gefitinib","score":0.9229999780654907},{"id":"https://openalex.org/keywords/fixed-dose-rate-infusion","display_name":"fixed dose rate infusion","score":0.9890000224113464},{"id":"https://openalex.org/keywords/metastatic-pancreatic-adenocarcinoma","display_name":"metastatic pancreatic adenocarcinoma","score":0.8769999742507935},{"id":"https://openalex.org/keywords/egfr-tyrosine-kinase-inhibitors","display_name":"EGFR tyrosine kinase inhibitors","score":0.9409999847412109},{"id":"https://openalex.org/keywords/maximum-tolerated-dose","display_name":"maximum tolerated dose","score":0.8069999814033508},{"id":"https://openalex.org/keywords/dose-limiting-toxicity","display_name":"dose-limiting toxicity","score":0.9890000224113464},{"id":"https://openalex.org/keywords/hematological-toxicity","display_name":"hematologic toxicity","score":0.8029999732971191},{"id":"https://openalex.org/keywords/granulocytopenia","display_name":"granulocytopenia","score":0.9480000138282776},{"id":"https://openalex.org/keywords/combination-chemotherapy","display_name":"combination chemotherapy","score":0.7329999804496765},{"id":"https://openalex.org/keywords/time-to-progression","display_name":"time to progression","score":0.6039999723434448},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.9940000176429749},{"id":"https://openalex.org/keywords/liver-metastases","display_name":"liver metastasis","score":0.546999990940094},{"id":"https://openalex.org/keywords/lung-metastasis","display_name":"lung metastasis","score":0.9850000143051147},{"id":"https://openalex.org/keywords/dose-escalation","display_name":"dose escalation","score":0.4399999976158142}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9315053820610046},{"id":"https://openalex.org/C2780258809","wikidata":"https://www.wikidata.org/wiki/Q414143","display_name":"Gemcitabine","level":3,"score":0.6959089040756226},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.5835788249969482},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5807022452354431},{"id":"https://openalex.org/C29730261","wikidata":"https://www.wikidata.org/wiki/Q274160","display_name":"Toxicity","level":2,"score":0.5726091265678406},{"id":"https://openalex.org/C2780210213","wikidata":"https://www.wikidata.org/wiki/Q212961","display_name":"Pancreatic cancer","level":3,"score":0.5244969725608826},{"id":"https://openalex.org/C2778248108","wikidata":"https://www.wikidata.org/wiki/Q5445","display_name":"Anemia","level":2,"score":0.49391108751296997},{"id":"https://openalex.org/C2780580887","wikidata":"https://www.wikidata.org/wiki/Q417824","display_name":"Gefitinib","level":4,"score":0.47136417031288147},{"id":"https://openalex.org/C2776907518","wikidata":"https://www.wikidata.org/wiki/Q1734165","display_name":"Performance status","level":3,"score":0.46557825803756714},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.44793757796287537},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.42606785893440247},{"id":"https://openalex.org/C2781182431","wikidata":"https://www.wikidata.org/wiki/Q356033","display_name":"Adenocarcinoma","level":3,"score":0.42382362484931946},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.41474443674087524},{"id":"https://openalex.org/C126894567","wikidata":"https://www.wikidata.org/wiki/Q105650","display_name":"Urology","level":1,"score":0.3473256528377533},{"id":"https://openalex.org/C2779438470","wikidata":"https://www.wikidata.org/wiki/Q424401","display_name":"Epidermal growth factor receptor","level":3,"score":0.0765562653541565}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2005.23.16_suppl.4118","doi":"https://doi.org/10.1200/jco.2005.23.16_suppl.4118","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2005.23.16_suppl.4118","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2011686032","https://openalex.org/W2246213330","https://openalex.org/W4236867716","https://openalex.org/W2265490807","https://openalex.org/W2241000821","https://openalex.org/W2246281693","https://openalex.org/W1983563802","https://openalex.org/W2088929665","https://openalex.org/W2087792099","https://openalex.org/W2379225776"],"abstract_inverted_index":{"4118":[0],"Background:":[1],"Patients":[2],"(pts)":[3],"with":[4,10,20,53,61,65,235,281,300],"metastatic":[5,28,165],"pancreatic":[6,67,177],"adenocarcinoma":[7],"(PCa)":[8],"treated":[9,130],"GEM":[11,47,71,292],"using":[12,48],"a":[13,16,49,86,227,323],"FDRI":[14,50,74,279,296],"have":[15],"longer":[17],"survival":[18,269],"than":[19],"30":[21],"min":[22],"infusion":[23],"schedules1.":[24],"Over":[25],"40%":[26],"of":[27,46,75,85,92,113,142,209,229,297,309],"PCa\u2019s":[29],"overexpress":[30],"EGFR2.":[31],"This":[32],"study":[33],"aimed":[34],"to":[35,265],"determine":[36],"the":[37,73,140],"maximum":[38],"tolerated":[39],"dose":[40,133,206,228,290],"(MTD)":[41],"and":[42,83,95,147,163,179,213,242,267,273,285],"dose-limiting":[43],"toxicities":[44],"(DLTs)":[45],"in":[51,59,139,238,245],"combination":[52],"gefitinib,":[54],"an":[55],"EGFR":[56],"TK":[57],"inhibitor":[58],"pts":[60,128,157,172,204,240,247],"PCa.":[62],"Methods:":[63],"Pts":[64],"advanced":[66],"cancer":[68],"were":[69,98,108,129,150,158,187,233,270],"given":[70,105],"at":[72,131,226,295],"10":[76,298],"mg/m2/min":[77,299],"IV":[78,118,124],"on":[79],"days":[80],"1,":[81],"8,":[82],"15":[84],"28":[87],"day":[88],"cycle.":[89],"Dose":[90,135],"levels":[91],"1000,":[93],"1200":[94,194],"1500":[96],"mg/m2":[97],"evaluated.":[99],"Oral":[100],"gefitinib":[101,282,301],"250":[102],"mg":[103],"was":[104,154,193,197,261],"daily.":[106,304],"DLTs":[107],"defined":[109],"as":[110],"two":[111],"instances":[112],"grade":[114,123,210,217,223,236,243,252],"III":[115],"hematologic":[116,125],"or":[117,121,161,258,331,334],"non-hematologic":[119],"toxicity":[120,260],"any":[122],"toxicity.":[126],"Four":[127,145],"each":[132],"level.":[134],"level":[136],"escalation":[137],"occurred":[138],"absence":[141],"DLTs.":[143],"Results:":[144],"women":[146],"8":[148],"men":[149],"enrolled.":[151],"Median":[152,185,263],"age":[153],"61.":[155],"All":[156],"PS":[159],"0":[160],"1":[162,214,237,305],"had":[164,216,222,251],"disease":[166],"(83.3%":[167],"liver;":[168],"16.6%":[169],"lungs).":[170],"Three":[171],"received":[173],"prior":[174],"chemoradiation":[175],"for":[176,182,291],"cancer,":[178],"one":[180],"chemotherapy":[181],"lung":[183],"cancer.":[184],"cycles":[186],"3":[188,211,218,224,253],"per":[189],"pt.":[190],"The":[191],"MTD":[192],"mg/m2.":[195],"Toxicity":[196],"predominantly":[198],"hematologic.":[199],"At":[200],"1500mg/m2,":[201],"all":[202],"4":[203],"required":[205],"reduction":[207],"because":[208],"granulocytopenia,":[212],"pt":[215,221,250],"anemia.":[219],"One":[220,249],"granulocytopenia":[225],"1200mg/m2.":[230],"Acneform":[231],"rashes":[232],"mild":[234],"6":[239],"(50%)":[241],"2":[244,246,314],"(16.6%).":[248],"vomiting;":[254],"no":[255],"significant":[256],"diarrhea":[257],"liver":[259],"seen.":[262],"time":[264],"progression":[266],"overall":[268],"3.6":[271],"months":[272],"4.8":[274],"months,":[275],"respectively.":[276],"Conclusions:":[277],"Combining":[278],"gemcitabine":[280],"is":[283,293],"feasible":[284],"tolerable.":[286],"Recommended":[287],"phase":[288],"II":[289],"1200mg/m2":[294],"250mg":[302],"PO":[303],"Tempero,":[306],"M.":[307],"Journal":[308],"Clinical":[310],"Oncology":[311],"21(18):3402\u20138,":[312],"2003.":[313],"Uegaki,":[315],"K.":[316],"Anticancer":[317],"Research":[318,340],"17:3841\u20137,":[319],"1997.":[320],"Supported":[321],"by":[322],"grant":[324],"from":[325],"AstraZeneca":[326,346,347],"Pharmaceuticals":[327],"Author":[328],"Disclosure":[329],"Employment":[330],"Leadership":[332],"Consultant":[333],"Advisory":[335],"Role":[336],"Stock":[337],"Ownership":[338],"Honoraria":[339],"Funding":[341],"Expert":[342],"Testimony":[343],"Other":[344],"Remuneration":[345]},"counts_by_year":[],"updated_date":"2026-10-14T16:39:01.820549","created_date":"2016-06-24T00:00:00"}